Citations (42)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Clara Cortell Fuster, María Amparo Martínez Gómez, Ana Cristina Cercós Lleti & Mónica Climente Martí. (2022) Topical rapamycin in the treatment of facial angiofibromas in tuberous sclerosis: a systematic review based on evidence. Journal of Dermatological Treatment 33:4, pages 1804-1810.
Read now
Read now
Romina Moavero, Federica Graziola, Gloria Romagnoli & Paolo Curatolo. (2016) Toward targeted treatments in tuberous sclerosis. Expert Opinion on Orphan Drugs 4:3, pages 243-253.
Read now
Read now
Articles from other publishers (40)
Phillip Aitken, Ioana Stanescu, Laura Boddington, Caroline Mahon, Andras Fogarasi, Yi-Hua Liao, Marta Ivars, Ester Moreno-Artero, Doris Trauner, Steven T DeRoos, Jasna Jancic, Milos Nikolic, Patrícia Balážová, Harper N Price, Kinga Hadzsiev, Kate Riney, Stacie Stapleton, Megha M Tollefson, Derek Bauer, Blanka Pinková & Hartley Atkinson. (2023) A novel rapamycin cream formulation improves facial angiofibromas associated with tuberous sclerosis complex: a double-blind randomized placebo-controlled trial. British Journal of Dermatology 189:5, pages 520-530.
Crossref
Crossref
Riccardo Balestri, Laura Rizzoli, Annalisa Pedrolli, Silvana Anna Maria Urru, Giulia Rech, Iria Neri, Carlo R. Girardelli & Michela Magnano. (2022)
Analysis of current data on the use of topical
mTOR
inhibitors in the treatment of facial angiofibromas in tuberous sclerosis complex—An update
. Journal of the European Academy of Dermatology and Venereology 37:3, pages 474-487.
Crossref
Crossref
Guillaume Le Guyader, Bernard Do, Ivo B. Rietveld, Pascale Coric, Serge Bouaziz, Jean-Michel Guigner, Philippe-Henri Secretan, Karine Andrieux & Muriel Paul. (2022) Mixed Polymeric Micelles for Rapamycin Skin Delivery. Pharmaceutics 14:3, pages 569.
Crossref
Crossref
Julie Quartier, Maria Lapteva, Younes Boulaguiem, Stéphane Guerrier & Yogeshvar N. Kalia. (2021) Polymeric micelle formulations for the cutaneous delivery of sirolimus: A new approach for the treatment of facial angiofibromas in tuberous sclerosis complex. International Journal of Pharmaceutics 604, pages 120736.
Crossref
Crossref
Guillaume Le Guyader, Bernard Do, Victoire Vieillard, Karine Andrieux & Muriel Paul. (2020) Comparison of the In Vitro and Ex Vivo Permeation of Existing Topical Formulations Used in the Treatment of Facial Angiofibroma and Characterization of the Variations Observed. Pharmaceutics 12:11, pages 1060.
Crossref
Crossref
P.L. Chen, J.B. Hong, L.J. Shen, Y.T. Chen, S.J. Wang & Y.H. Liao. (2020) The efficacy and safety of topical rapamycin–calcitriol for facial angiofibromas in patients with tuberous sclerosis complex: a prospective, double‐blind, randomized clinical trial. British Journal of Dermatology 183:4, pages 655-663.
Crossref
Crossref
Sophie Leducq, Bruno Giraudeau, Elsa Tavernier & Annabel Maruani. (2019) Topical use of mammalian target of rapamycin inhibitors in dermatology: A systematic review with meta-analysis. Journal of the American Academy of Dermatology 80:3, pages 735-742.
Crossref
Crossref
Margaret C. Wheless, Apana A. Takwi, Hassan Almoazen & James W. Wheless. (2019) Long-Term Exposure and Safety of a Novel Topical Rapamycin Cream for the Treatment of Facial Angiofibromas in Tuberous Sclerosis Complex: Results From a Single-Center, Open-Label Trial. Child Neurology Open 6, pages 2329048X1983504.
Crossref
Crossref
Mari Wataya-Kaneda, Yuuki Ohno, Yasuyuki Fujita, Hiroo Yokozeki, Hironori Niizeki, Masaaki Ogai, Kazuyoshi Fukai, Hiroshi Nagai, Yuichi Yoshida, Izumi Hamada, Taihei Hio, Kenji Shimizu & Hiroyuki Murota. (2018) Sirolimus Gel Treatment vs Placebo for Facial Angiofibromas in Patients With Tuberous Sclerosis Complex. JAMA Dermatology 154:7, pages 781.
Crossref
Crossref
Senfen Wang, Yuanxiang Liu, Jinghai Wei, Jian Zhang, Zhaoyang Wang & Zigang Xu. (2017) Tuberous Sclerosis Complex in 29 Children: Clinical and Genetic Analysis and Facial Angiofibroma Responses to Topical Sirolimus. Pediatric Dermatology 34:5, pages 572-577.
Crossref
Crossref
Nausicaa Malissen, Laurence Vergely, Marguerite Simon, Agathe Roubertie, Marie-Claire Malinge & Didier Bessis. (2017) Long-term treatment of cutaneous manifestations of tuberous sclerosis complex with topical 1% sirolimus cream: A prospective study of 25 patients. Journal of the American Academy of Dermatology 77:3, pages 464-472.e3.
Crossref
Crossref
Ana Batalla, ?ngeles Fl?rez, Carmen D?vila-Pousa & Carlos de la Torre. (2016) Utilidad de la rapamicina t?pica en dermatolog?a pedi?trica. Piel 31:10, pages 715-720.
Crossref
Crossref
Ana Batalla, ?ngeles Fl?rez, Carmen D?vila Pousa & Carlos de la Torre. (2016) Rapamicina t?pica y angiofibromas faciales en la esclerosis tuberosa. Piel 31:7, pages 467-470.
Crossref
Crossref
Sergiusz J??wiak, Krzysztof Sadowski, Katarzyna Kotulska & Robert A. Schwartz. (2016) Topical Use of Mammalian Target of Rapamycin (mTOR) Inhibitors in Tuberous Sclerosis Complex?A Comprehensive Review of the Literature. Pediatric Neurology 61, pages 21-27.
Crossref
Crossref
Gaurav Shah, Sotirios Stergiopoulos & David Lebwohl. 2016. mTOR Inhibition for Cancer Therapy: Past, Present and Future. mTOR Inhibition for Cancer Therapy: Past, Present and Future
113
137
.
Stephanie K. Jacks & Patricia M. Witman. (2015) Tuberous Sclerosis Complex: An Update for Dermatologists. Pediatric Dermatology 32:5, pages 563-570.
Crossref
Crossref
Alexander L. Fogel, Sharleen Hill & Joyce M.C. Teng. (2015) Advances in the therapeutic use of mammalian target of rapamycin (mTOR) inhibitors in dermatology. Journal of the American Academy of Dermatology 72:5, pages 879-889.
Crossref
Crossref
R. Balestri, I. Neri, A. Patrizi, L. Angileri, L. Ricci & M. Magnano. (2014) Analysis of current data on the use of topical rapamycin in the treatment of facial angiofibromas in Tuberous Sclerosis Complex. Journal of the European Academy of Dermatology and Venereology 29:1, pages 14-20.
Crossref
Crossref
N. Knöpfel, A. Martín-Santiago, A. Bauza & J.A. Hervás. (2014) Topical 0.2% Rapamycin to Treat Facial Angiofibromas and Hypomelanotic Macules in Tuberous Sclerosis. Actas Dermo-Sifiliográficas (English Edition) 105:8, pages 802-803.
Crossref
Crossref
N. Kn?pfel, A. Mart?n-Santiago, A. Bauza & J.A. Herv?s. (2014) Rapamicina t?pica al 0,2% para el tratamiento de angiofibromas faciales y m?culas hipomelan?ticas en la esclerosis tuberosa. Actas Dermo-Sifiliogr?ficas 105:8, pages 802-803.
Crossref
Crossref
Patricia E. Dill, Gaston De Bernardis, Peter Weber & Uli L?sch. (2014) Topical Everolimus for Facial Angiofibromas in the Tuberous Sclerosis Complex. A First Case Report. Pediatric Neurology 51:1, pages 109-113.
Crossref
Crossref
R. Salido-Vallejo, G. Garnacho-Saucedo & J.C. Moreno-Giménez. (2014) Current Options for the Treatment of Facial Angiofibromas. Actas Dermo-Sifiliográficas (English Edition) 105:6, pages 558-568.
Crossref
Crossref
R. Salido-Vallejo, G. Garnacho-Saucedo & J.C. Moreno-Giménez. (2014) Opciones terapéuticas actuales para los angiofibromas faciales. Actas Dermo-Sifiliográficas 105:6, pages 558-568.
Crossref
Crossref
Lieke M. C. Gijezen, Marigje Vernooij, Herm Martens, Charlene E. U. Oduber, Charles J. M. Henquet, Theo M. Starink, Martin H. Prins, Fred H. Menko, Patty J. Nelemans & Maurice A. M. van Steensel. (2014) Topical Rapamycin as a Treatment for Fibrofolliculomas in Birt-Hogg-Dub? Syndrome: A Double-Blind Placebo-Controlled Randomized Split-Face Trial. PLoS ONE 9:6, pages e99071.
Crossref
Crossref
Gang Ma, Pinru Wu, Xiaoxi Lin, Hui Chen, Wei Li, Xiaojie Hu & Yunbo Jin. (2014) Nd:YAG laser for “fractional” treatment of angiofibromas. International Journal of Dermatology 53:5, pages 638-642.
Crossref
Crossref
Jung-Yi Lisa Chan, Kuo-Hsien Wang, Chia-Lang Fang & Wei-Yu Chen. (2014) Fibrous Papule of the Face, Similar to Tuberous Sclerosis Complex-Associated Angiofibroma, Shows Activation of the Mammalian Target of Rapamycin Pathway: Evidence for a Novel Therapeutic Strategy?. PLoS ONE 9:2, pages e89467.
Crossref
Crossref
Jenny Tu, Rachael S Foster, Lewis J Bint & Anne R Halbert. (2014) Topical rapamycin for angiofibromas in paediatric patients with tuberous sclerosis: Follow up of a pilot study and promising future directions. Australasian Journal of Dermatology 55:1, pages 63-69.
Crossref
Crossref
Jin Park, Seok-Kweon Yun, Yong-Sun Cho, Ki-Hun Song & Han-Uk Kim. (2014) Treatment of Angiofibromas in Tuberous Sclerosis Complex: The Effect of Topical Rapamycin and Concomitant Laser Therapy. Dermatology 228:1, pages 37-41.
Crossref
Crossref
Omar Pacha & Adelaide Hebert. 2014. Acneiform Eruptions in Dermatology. Acneiform Eruptions in Dermatology
229
233
.
M. Tanaka, M. Wataya-Kaneda, A. Nakamura, S. Matsumoto & I. Katayama. (2013) First left-right comparative study of topical rapamycin vs. vehicle for facial angiofibromas in patients with tuberous sclerosis complex. British Journal of Dermatology 169:6, pages 1314-1318.
Crossref
Crossref
James W. Wheless & Hassan Almoazen. (2013) A Novel Topical Rapamycin Cream for the Treatment of Facial Angiofibromas in Tuberous Sclerosis Complex. Journal of Child Neurology 28:7, pages 933-936.
Crossref
Crossref
Romina Moavero, Antonella Coniglio, Francesco Garaci & Paolo Curatolo. (2013) Is mTOR inhibition a systemic treatment for tuberous sclerosis?. Italian Journal of Pediatrics 39:1, pages 57.
Crossref
Crossref
Susan M. Huson & Bruce R. Korf. 2013. Emery and Rimoin's Principles and Practice of Medical Genetics. Emery and Rimoin's Principles and Practice of Medical Genetics
1
45
.
Constantine Gennatas, Vasiliki Michalaki, Paraskevi Vasilatou Kairi, Agathi Kondi-Paphiti & Dionysios Voros. (2012) Successful treatment with the mTOR inhibitor everolimus in a patient with Perivascular epithelioid cell tumor. World Journal of Surgical Oncology 10:1.
Crossref
Crossref
Mustafa Sahin. (2012) Targeted treatment trials for tuberous sclerosis and autism: no longer a dream. Current Opinion in Neurobiology 22:5, pages 895-901.
Crossref
Crossref
I. Cuevas Asencio, R. Albornoz López, R. Salido Vallejo & M. Reyes Malia. (2012) Formulación de sirolimus tópico al 0,4% para el tratamiento de angiofibromas faciales. Farmacia Hospitalaria 36:5, pages 433-434.
Crossref
Crossref
Mary Kay Koenig, Adelaide A. Hebert, Joan Roberson, Joshua Samuels, John Slopis, Audrey Woerner & Hope Northrup. (2012) Topical Rapamycin Therapy to Alleviate the Cutaneous Manifestations of Tuberous Sclerosis Complex. Drugs in R&D 12:3, pages 121-126.
Crossref
Crossref
P. Valerón-Almazán, M. Vitiello, A. Abuchar & F.A. Kerdel. (2012) Topical Rapamycin Solution to Treat Multiple Facial Angiofibromas in a Patient With Tuberous Sclerosis. Actas Dermo-Sifiliográficas (English Edition) 103:2, pages 165-167.
Crossref
Crossref
M. Wataya‐Kaneda, M. Tanaka, A. Nakamura, S. Matsumoto & I. Katayama. (2011) A topical combination of rapamycin and tacrolimus for the treatment of angiofibroma due to tuberous sclerosis complex (TSC): a pilot study of nine Japanese patients with TSC of different disease severity. British Journal of Dermatology 165:4, pages 912-916.
Crossref
Crossref
W van Veelen, S E Korsse, L van de Laar & M P Peppelenbosch. (2011) The long and winding road to rational treatment of cancer associated with LKB1/AMPK/TSC/mTORC1 signaling. Oncogene 30:20, pages 2289-2303.
Crossref
Crossref